Colitis - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 80 pages report, published by Global Markets Direct

Keywords : Colitis Therapeutic Products under Development, Key Players in Colitis Therapeutics, Colitis Pipeline Overview, Colitis Pipeline, Colitis Pipeline Assessment

Report ThumbnailSeptember-2013
Colitis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Colitis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Colitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colitis. Colitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Colitis.
- A review of the Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Colitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Colitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Colitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Colitis, H2 2013 9
  • Products under Development for Colitis - Comparative Analysis, H2 2013 10
  • Products under Development by Companies, H2 2013 11
  • Products under Investigation by Universities/Institutes, H2 2013 13
  • Mid Clinical Stage Products, H2 2013 14
  • Discovery and Pre-Clinical Stage Products, H2 2013 15
  • Assessment by Monotherapy Products, H2 2013 31
  • Assessment by Route of Administration, H2 2013 32
  • Assessment by Stage and Route of Administration, H2 2013 33
  • Assessment by Molecule Type, H2 2013 34
  • Assessment by Stage and Molecule Type, H2 2013 35
  • List of Tables
  • Number of Products Under Development for Colitis, H2 2013 9
  • Products under Development for Colitis - Comparative Analysis, H2 2013 10
  • Number of Products under Development by Companies, H2 2013 12
  • Number of Products under Investigation by Universities/Institutes, H2 2013 13
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 14
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 15
  • Products under Development by Companies, H2 2013 16
  • Products under Investigation by Universities/Institutes, H2 2013 17
  • Baxter International Inc., H2 2013 18
  • Inovio Biomedical Corporation, H2 2013 19
  • Euroscreen S.A., H2 2013 20
  • BioLineRx, Ltd., H2 2013 21
  • Idera Pharmaceuticals, Inc., H2 2013 22
  • Lpath, Inc., H2 2013 23
  • Innate Pharma SA, H2 2013 24
  • NasVax Ltd., H2 2013 25
  • Lycera Corp., H2 2013 26
  • Zyngenia, Inc., H2 2013 27
  • N30 Pharmaceuticals, H2 2013 28
  • Atlantic Healthcare Limited, H2 2013 29
  • CellAct Pharma GmbH, H2 2013 30
  • Assessment by Monotherapy Products, H2 2013 31
  • Assessment by Stage and Route of Administration, H2 2013 33
  • Assessment by Stage and Molecule Type, H2 2013 35
  • Colitis Therapeutics - Drug Profile Updates 66
  • Colitis Therapeutics - Dormant Products 75
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Colitis Overview 8
  • Therapeutics Development 9
  • An Overview of Pipeline Products for Colitis 9
  • Colitis Therapeutics under Development by Companies 11
  • Colitis Therapeutics under Investigation by Universities/Institutes 13
  • Mid Clinical Stage Products 14
  • Comparative Analysis 14
  • Discovery and Pre-Clinical Stage Products 15
  • Comparative Analysis 15
  • Colitis Therapeutics - Products under Development by Companies 16
  • Colitis Therapeutics - Products under Investigation by Universities/Institutes 17
  • Companies Involved in Colitis Therapeutics Development 18
  • Baxter International Inc. 18
  • Inovio Biomedical Corporation 19
  • Euroscreen S.A. 20
  • BioLineRx, Ltd. 21
  • Idera Pharmaceuticals, Inc. 22
  • Lpath, Inc. 23
  • Innate Pharma SA 24
  • NasVax Ltd. 25
  • Lycera Corp. 26
  • Zyngenia, Inc. 27
  • N30 Pharmaceuticals 28
  • Atlantic Healthcare Limited 29
  • CellAct Pharma GmbH 30
  • Colitis - Therapeutics Assessment 31
  • Assessment by Monotherapy Products 31
  • Assessment by Route of Administration 32
  • Assessment by Molecule Type 34
  • Drug Profiles 36
  • IMO-3100 - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • Asonep - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • BL-5040 - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • VGX-1027 - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • NSD-726 - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • N-6022 - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • Anti-CD3 Mab - Drug Profile 45
  • Product Description 45
  • Mechanism of Action 45
  • R&D Progress 45
  • N-6547 - Drug Profile 47
  • Product Description 47
  • Mechanism of Action 47
  • R&D Progress 47
  • BAX-69 - Drug Profile 48
  • Product Description 48
  • Mechanism of Action 48
  • R&D Progress 48
  • ESN-282 - Drug Profile 50
  • Product Description 50
  • Mechanism of Action 50
  • R&D Progress 50
  • BRA-101 - Drug Profile 51
  • Product Description 51
  • Mechanism of Action 51
  • R&D Progress 51
  • Bioenergetics Program - Drug Profile 52
  • Product Description 52
  • Mechanism of Action 52
  • R&D Progress 52
  • IPH-33 Program - Drug Profile 53
  • Product Description 53
  • Mechanism of Action 53
  • R&D Progress 53
  • CAP-2.1 - Drug Profile 54
  • Product Description 54
  • Mechanism of Action 54
  • R&D Progress 54
  • CAP-2.2 - Drug Profile 55
  • Product Description 55
  • Mechanism of Action 55
  • R&D Progress 55
  • Cathelicidin - Drug Profile 56
  • Product Description 56
  • Mechanism of Action 56
  • R&D Progress 56
  • TRP Antagonist - Drug Profile 57
  • Product Description 57
  • Mechanism of Action 57
  • R&D Progress 57
  • IP-1510 - Drug Profile 58
  • Product Description 58
  • Mechanism of Action 58
  • R&D Progress 58
  • Helminth-Derived Peptides - Drug Profile 59
  • Product Description 59
  • Mechanism of Action 59
  • R&D Progress 59
  • Pannexin-1 Inhibitors - Drug Profile 60
  • Product Description 60
  • Mechanism of Action 60
  • R&D Progress 60
  • Bi-Specific Anti-TNFalpha/Ang2 Zybody - Drug Profile 61
  • Product Description 61
  • Mechanism of Action 61
  • R&D Progress 61
  • auranofin - Drug Profile 62
  • Product Description 62
  • Mechanism of Action 62
  • R&D Progress 62
  • NK-007 - Drug Profile 63
  • Product Description 63
  • Mechanism of Action 63
  • R&D Progress 63
  • C-142 - Drug Profile 64
  • Product Description 64
  • Mechanism of Action 64
  • R&D Progress 64
  • Genetically Engineered Treg Cells - Drug Profile 65
  • Product Description 65
  • Mechanism of Action 65
  • R&D Progress 65
  • Colitis Therapeutics - Drug Profile Updates 66
  • Colitis Therapeutics - Dormant Products 75
  • Colitis - Product Development Milestones 76
  • Featured News & Press Releases 76
  • Mar 22, 2013: Lpath Receives Key European And US Patents Related To Anti-cancer Drug Program ASONEP 76
  • Mar 18, 2009: ViroPharma Submits Comments on Vancocin Draft Bioequivalence Guidance 77
  • Dec 18, 2008: ViroPharma Files FOIA Complaint Seeking Administrative Record for Vancocin 77
  • Dec 15, 2008: ViroPharma Provides Update on Vancocin 78
  • Appendix 79
  • Methodology 79
  • Coverage 79
  • Secondary Research 79
  • Primary Research 79
  • Expert Panel Validation 79
  • Contact Us 80
  • Disclaimer 80

Please select a license type

Share

Related Products

Global Markets DirectColitis - Pipeline Review, H2 2013Product ThumbnailColitis - Pipeline Review, H2 2013, Industry ReportProduct #: 113302
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved